Comparing SG&A Expenses: Amgen Inc. vs Pharming Group N.V. Trends and Insights

SG&A Expenses: A Tale of Two Biotech Giants

In the competitive world of biotechnology, understanding the financial strategies of industry leaders is crucial. Amgen Inc. and Pharming Group N.V. offer a fascinating study in contrasts when it comes to Selling, General, and Administrative (SG&A) expenses from 2014 to 2023.

Amgen Inc.: A Steady Climb

Amgen's SG&A expenses have shown a consistent upward trend, increasing by approximately 31% over the decade. This growth reflects Amgen's strategic investments in marketing and administration, crucial for maintaining its position as a biotech leader.

Pharming Group N.V.: A Rapid Surge

In contrast, Pharming Group N.V. experienced a staggering increase of over 2,000% in SG&A expenses, highlighting its aggressive expansion and market penetration efforts. Despite starting from a smaller base, Pharming's growth trajectory underscores its ambition to challenge larger competitors.

This comparison not only reveals the differing strategies of these companies but also provides insights into the broader biotech industry's financial dynamics.